TMS is not an established treatment for autism. No TMS device is FDA-cleared for autism spectrum disorder, so any use for core autism traits is off-label and research-stage. A 2026 meta-analysis of 53 randomized trials found improvements on several rating scales, but rated the certainty of that evidence "low to very low" and concluded that rTMS "cannot yet be recommended as routine clinical treatment" for autism.
Where TMS does have a clear role is a different question: an autistic adult, or a teenager in the cleared age range, who also has major depression that has not responded to medication. That is a depression decision, made on depression evidence. This page separates the two, because marketing for "TMS for autism" often blurs them.
What the FDA has and has not cleared
FDA clearances for TMS cover a short list of indications: major depressive disorder in adults, obsessive-compulsive disorder as an adjunct, short-term smoking cessation, migraine and, most recently, PTSD as an adjunct. Since 2024, several systems also carry a label for depression in adolescents aged 15 to 21, as an add-on to medication. Autism is not on the list, and no clearance for it was found in the FDA records reviewed for this hub. For background on what "cleared" means, see how FDA clearance works for TMS devices.
Insurers follow the same line. Optum's behavioral policy, which governs UnitedHealthcare members, lists autism among the indications for which TMS is unproven. Families should expect to pay out of pocket for any autism-directed TMS, and should read that as a signal about the evidence, not only about cost. The UnitedHealthcare and Optum coverage guide covers the criteria in detail.
What the research actually shows
The autism literature is large in study count and small in reliable answers. Most trials are short, enroll children, use different coils, targets and frequencies, and measure outcomes with parent or clinician rating scales that are sensitive to expectation.
| Study | Design | What it found | What limits it |
|---|---|---|---|
| Mei et al., Psychiatry Research, 2026 | Meta-analysis of 53 RCTs | Improvement on several autism scales; adverse events mild where reported | 85% of trials open-label; certainty "low to very low" |
| Ni et al., Autism Research, 2023 | Double-blind, sham-controlled; 60 participants aged 8 to 30, 16 sessions of cTBS to the left DLPFC | Active was not better than sham on any clinical or cognitive measure at week 8 or week 12; both groups improved | One target and one protocol |
| Tan et al., BMJ, 2026 | Multicenter, sham-controlled; 200 children aged 4 to 10, accelerated cTBS to the left motor cortex for five days | Greater reduction in SRS-2 social-communication scores than sham after treatment and at one month (Cohen's d about 0.9) | One-month follow-up; needs replication outside the original sites |
The two blinded trials point in opposite directions. The negative 2023 trial is instructive: its authors note that earlier positive open-label results may have reflected generalized or placebo effects, because the sham group improved about as much as the active group. The positive 2026 BMJ trial is the strongest signal to date, but it tested a specific accelerated protocol over a short horizon in one country. Neither supports a clinic selling a standard course of TMS for autism today.
Why open-label results look better than they are
In autism research, a family that has sought out a novel treatment, rearranged its schedule for daily sessions and invested hope in the outcome is primed to notice change. Outcome scales are often completed by those same parents. Sham response is also large in TMS studies generally: in depression trials, people receiving sham stimulation improve substantially. Without a sham arm and blinded raters, that improvement is indistinguishable from a treatment effect. The same caution applies to the closely related research on TMS for ADHD.
Safety questions that matter more in autism
TMS is generally well tolerated, and the autism trials report mostly mild, transient side effects. But the safety reporting is thin: in the 2026 meta-analysis, just over half of the included studies did not explicitly report safety data. Several autism-specific factors deserve attention before anyone proceeds.
- Epilepsy. Seizure is the most serious acute risk of TMS, and the risk rises substantially in people with epilepsy or brain lesions. Epilepsy is far more common in autistic people than in the general population; a systematic review of 74 studies put its median prevalence at 12.1%. A personal or family seizure history, or an abnormal EEG, needs a neurologist's input first. The broader picture is in TMS safety and seizure risk.
- Seizure-threshold medications. FDA device guidance asks for close monitoring of patients taking drugs known to lower the seizure threshold, including neuroleptic medications, which some autistic children take for irritability.
- Sound and sensory load. The coil's click peaks near the 140 dB limit for impulsive noise, and earplugs rated for 30 dB of noise reduction are required. A child with sound sensitivity who pulls out an earplug mid-session is a real hearing risk, not a theoretical one.
- Tolerating the procedure. TMS requires sitting still with a coil pressed to the scalp, sometimes with face or scalp twitching. Forcing a distressed child through sessions is not a neutral trade-off for an unproven benefit.
Where TMS can be reasonable: depression in an autistic person
Depression occurs in autistic adolescents and adults and can be missed, because flat affect, withdrawal or irritability get attributed to autism itself. When an autistic adult has major depression that has not improved with antidepressants, TMS is assessed exactly as it would be for anyone else, under the cleared depression indication. The same applies to adolescents aged 15 to 21 under the adjunctive labels, alongside medication. The patient-facing guide to TMS for teens and young adults explains what that clearance does and does not mean.
Autism itself is not among the contraindications in FDA guidance, which center on implanted metal and stimulators in or near the head. Practical adaptations help: a pre-visit to see the room and hear the click, visual schedules, a consistent technician, and building up to full sessions. The goal is a depression response, measured on depression scales, not a change in autistic traits.
If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.
Questions to ask any clinic offering TMS for autism
- What is the indication? If it is autism traits rather than depression, ask the clinic to say plainly that this is off-label and research-stage.
- Which published, sham-controlled trial does your protocol copy, and in what age group?
- How will you measure change, and who completes the rating scales?
- Who screened for epilepsy, and was an EEG or neurology review done?
- What happens if my child cannot tolerate a session? Are we committed to paying for a full course?
- Is this part of a registered clinical trial? A registered trial adds oversight and a defined protocol; if this is not one, ask why not.
A clinic that promises improved speech, social skills or "rewiring" is selling beyond the evidence. TMS protocols vary widely; the newer patterned approaches are explained in theta burst stimulation (iTBS and cTBS).
What to do instead, and alongside
For core autism-related challenges, the established supports remain behavioral, developmental, educational, speech and occupational therapies, with medication for specific target symptoms such as severe irritability, anxiety, sleep problems or co-occurring ADHD. For autistic people with depression or anxiety, adapted psychotherapy and careful medication trials come first. The site's autism resources and child and adolescent psychiatry pages describe that broader approach.
If a family wants to contribute to the evidence, a well-run, sham-controlled trial is the right place to try TMS for autism. Outside a trial, the honest summary is that the question is open. For how TMS fits in depression care more broadly, start at the TMS guide or the TMS overview.
Frequently asked questions
Is TMS FDA-cleared for autism?
No. TMS devices are cleared for depression, OCD, smoking cessation, migraine and PTSD, with adolescent depression labels for ages 15 to 21. Using TMS to treat autism traits is off-label.
Can TMS improve speech or social skills in autistic children?
Some trials report gains on social-communication rating scales, and one large 2026 trial was positive at one month. Another blinded trial found no benefit over sham. The evidence is not strong enough for routine use.
Is TMS safe for an autistic child?
Side effects in trials are usually mild, but seizure risk is higher in people with epilepsy, which is more common in autism, and the coil's loud click requires reliable hearing protection. Safety reporting in autism studies is incomplete.
Can an autistic adult with depression have TMS?
Yes, when the depression meets the usual criteria, such as not improving with antidepressants. Autism itself is not a listed contraindication. The decision rests on depression evidence and a seizure-risk screen.
Will insurance pay for TMS for autism?
Generally no. Optum's behavioral policy, for example, lists autism as an unproven indication. Coverage may apply if the treatment is for qualifying major depression.
Sources
- FDA 510(k) K083538. U.S. FDA, 2008. accessdata.fda.gov
- FDA 510(k) K160703 and K161519. U.S. FDA, 2016. accessdata.fda.gov
- FDA 510(k) K231926. U.S. FDA, 2024. accessdata.fda.gov
- De Novo Classification Request DEN170078. U.S. FDA, 2018. accessdata.fda.gov
- FDA 510(k) K200957 and K203616. U.S. FDA, 2020. accessdata.fda.gov
- 510(k) Premarket Notification. U.S. FDA, 2024. accessdata.fda.gov
- FDA 510(k) K260402. U.S. FDA, 2026. accessdata.fda.gov
- De Novo Classification Request DEN130022. U.S. FDA, 2013. accessdata.fda.gov
- A systematic review and meta-analysis on placebo response to repetitive transcranial magnetic stimulation for depression trials. Prog Neuropsychopharmacol Biol Psychiatry, 2018. pubmed.ncbi.nlm.nih.gov
- Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology, 2021. europepmc.org
- Seizures from transcranial magnetic stimulation 2012-2016: Results of a survey of active laboratories and clinics. Clinical Neurophysiology, 2019. europepmc.org
- Class II Special Controls Guidance Document: Repetitive Transcranial Magnetic Stimulation (rTMS) Systems. U.S. FDA, 2011. fda.gov
- Repetitive transcranial magnetic stimulation for autism spectrum disorder: A systematic review and meta-analysis of treatment regimens, efficacy, and safety. Psychiatry Research, 2026. europepmc.org
- Behavioral Clinical Policy: Transcranial Magnetic Stimulation. Optum Behavioral Health Solutions, 2025. providerexpress.com
- A lack of efficacy of continuous theta burst stimulation over the left dorsolateral prefrontal cortex in autism: A double blind randomized sham-controlled trial. Autism Research, 2023. europepmc.org
- Accelerated continuous theta burst stimulation targeting left primary motor cortex for children with autism spectrum disorder: multicentre randomised sham controlled trial. BMJ, 2026. europepmc.org
- The co-occurrence of epilepsy and autism: A systematic review. Epilepsy & Behavior, 2019. europepmc.org
Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.
The information provided on this blog is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
A Message From Dr. Lewis If you’ve been struggling with depression or anxiety, I want you to know something important:
The Conversation That Surprised Me A few years ago, I had a patient named Greg who’d been on escitalopram (Lexapro)
You’re Not Meant to Go Through Life Alone In our increasingly connected yet often isolating world, you might sometimes feel